5mg vial
Semaglutide is a 31-amino-acid GLP-1 analogue with 94% sequence homology to native GLP-1, modified with a C-18 fatty diacid chain enabling albumin binding and a approx. 7-day half-life. It is the most clinically validated peptide in the GLP-1 class, with extensive Phase 3 data across obesity, type 2 diabetes, cardiovascular, hepatic and neurological research areas.
Checking availability…
Activates GLP-1R on pancreatic β-cells to enhance glucose-dependent insulin secretion and suppress glucagon, while acting on hypothalamic GLP-1 receptors to reduce appetite and delay gastric emptying.
Standard research titration: 0.25mg weekly (weeks 1–4) → 0.5mg (weeks 5–8) → 1.0mg (weeks 9–12) → 1.7mg (weeks 13–16) → 2.4mg weekly maintenance. Subcutaneous (abdomen, thigh or upper arm). Research protocols typically 12–68 weeks.
approx. 168 hours (approx. 7 days), supporting once-weekly dosing.
Reconstitute a 5mg vial with 2mL bacteriostatic water for a 2.5mg/mL working concentration. Swirl gently and allow to sit 2–3 minutes; do not shake.
Lyophilised: 2–8°C (stable approx. 36 months frozen); short-term room-temperature use acceptable. Reconstituted: 2–8°C, do not freeze, use within 28 days.